Prostate cancer: Three drug trials to watch
Today (19 November) marks International Men’s Day with the theme for 2024 being Men's Health Champions, shining a light on…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.
-
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
-
Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…
-
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy
Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial…
-
Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants
Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase…
-
Trump triumphs but impact on healthcare industry remains unclear
Donald Trump has been elected 47th president of the US after the 5 November election having won more than the…
-
Viking stock fluctuates amid manufacturing concerns with obesity pill
Shares in Viking Therapeutics jumped after the company shared positive data from an early-stage trial of its obesity pill but…
-
Endeveco Bio spin-off to launch obesity trial
Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials. The candidate, 710GO,…
-
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with…
-
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
Johnson & Johnson (J&J) and Eli Lilly have both revealed the efficacy of their interleukin-23 (IL-23) inhibitors to treat Crohn’s…